Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Ethical Responsibility in the Off-Label Use of AI in Medical Imaging.

PMID: 42127793 ·

H, e, a, t, h, e, r, , M, , W, h, i, t, n, e, y, ;, , M, a, r, s, h, a, l, l, , H, , C, h, i, n, ;, , M, a, r, y, e, l, l, e, n, , L, , G, i, g, e, r

JournalThe Journal of clinical ethics
Year
PMID42127793

Abstract

AbstractArtificial intelligence in medical imaging (AI-MI), categorized by the U.S. Food and Drug Administration (FDA) as "Software as a Medical Device," can offer significant benefit to medical care. FDA approval-represented by a "label"-indicates that the device has demonstrated safety and efficacy for a specific clinical task and population for which the device is intended. Off-label use of AI-MI outside of the task and/or population can be medically and ethically problematic, yet benefits ma

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.

↑